clinical cases DDIs

Date of report 13 May 2019

Reported case interaction between **Cobicistat** and **Alprazolam**

Drugs suspected to be involved in the DDI

Perpetrator
Cobicistat

Daily Dose
150 (mg)

Dose adjustment performed
No

Administration Route
Oral

Start date
Unknown

End date
Ongoing

Victim
Alprazolam

Daily Dose
0.75 (mg)

Dose adjustment performed
No

Administration Route
Oral

Start date
Unknown

End date
Ongoing

Complete list of drugs taken by the patient

Antiretroviral treatment

Darunavir/Cobicistat
Raltegravir
Lamivudine

Complete list of all comedications taken by the patient, included that involved in the DDI

alprazolam, escitalopram, ipratropium bromide, salbutamol

Clinical case description

Gender

Female

Age

56

eGFR (mL/min)

>60

Liver function impairment

No

Description

Female patient with potential DDI between DRV/c and alprazolam. No toxicity was observed

Clinical Outcome

No unwanted outcome

Editorial Comment

Coadministration has not been studied. Alprazolam is mainly metabolized by CYP3A4. Coadministration of darunavir/

cobicistat may increase alprazolam concentrations and may result in enhanced sedation. A decrease in alprazolam dose may be needed.

University of Liverpool Recommendation

■ Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration

For more information click here